Prior Immune Checkpoint Inhibitor Treatment Is a Risk Factor for Treatment‐Related Adverse Events in Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab

Prior Immune Checkpoint Inhibitor Treatment Is a Risk Factor for Treatment‐Related Adverse Events in Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab

ABSTRACT Aims In March 2024, the American Society of Clinical Oncology recommended the combination of tremelimumab plus durvalumab as a treatment for advanced hepatocellular carcinoma (HCC). Although safety data for first‐line treatments are available, information on adverse events related to late‐l...

Full description

Saved in:

Bibliographic Details
Main Authors:	Naohiro Watanabe, Takashi Kobayashi, Michihiro Iwaki, Asako Nogami, Naohiro Wada, Ayako Shimizu, Tomoya Komori, Hirofumi Koike, Yukiko Sahashi, Atsushi Nakajima, Masato Yoneda
Format:	Article
Language:	English
Published:	Wiley 2025-04-01
Series:	JGH Open
Subjects:	durvalumab immune checkpoint inhibitors treatment‐related adverse events tremelimumab unresectable hepatocellular carcinoma
Online Access:	https://doi.org/10.1002/jgh3.70163
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Initial treatment efficacy and safety of durvalumab plus tremelimumab combination therapy in unresectable hepatocellular carcinoma in clinical practice
by: Tetsu Tomonari, et al.
Published: (2024-10-01)

Adverse drug reaction to tremelimumab and durvalumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database
by: Wei Fan Sui, et al.
Published: (2025-08-01)

Higher Absolute Lymphocyte Counts and Lower Des‐γ‐Carboxyprothrombin Levels After Treatment Initiation Are Associated With the Clinical Efficacy of Tremelimumab Plus Durvalumab Combination Therapy for Hepatocellular Carcinoma
by: Yuta Inoue, et al.
Published: (2025-02-01)

Development of shellfish allergy after exposure to dual immune checkpoint blockade
by: Zachary J Brown, et al.
Published: (2018-01-01)

Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) in patients with unresectable biliary tract cancer treated with gemcitabine, cisplatin, and durvalumab
by: Satoshi Mii, et al.
Published: (2025-07-01)

Immune checkpoint inhibitor-induced dyshidrotic eczema following tremelimumab therapy for hepatocellular carcinoma
by: Raphaella Lambert, BA, et al.
Published: (2025-04-01)

Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events
by: Yu Miura, et al.
Published: (2020-05-01)

PD-L1 pfeRNAs as blood-based predictors of treatment response of unresectable malignant pleural mesothelioma patients administered Durvalumab with cisplatin and pemetrexed as first-line therapy
by: Andrei Gurau, et al.
Published: (2025-06-01)

Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations
by: Jason C.S. Ho, et al.
Published: (2024-01-01)

Durvalumab Combined With Pemetrexed-Based Chemotherapy in Trial-Ineligible Patients With Mesothelioma: A Brief Report
by: Ibiayi Dagogo-Jack, MD, et al.
Published: (2025-05-01)

High-Grade Pneumonitis Events in Patients With Unresectable, Locally Advanced NSCLC Treated With Definitive Chemoradiation Followed by Adjuvant Durvalumab
by: Ciani Ellison, MD, et al.
Published: (2024-12-01)

Extrapulmonary small cell carcinoma of the liver treated with chemotherapy and durvalumab
by: Alfredo S. Golemba, MD, et al.
Published: (2025-05-01)

Descriptive analysis of durvalumab use in unresectable stage III non-small cell lung cancer in patients treated in Quebec’s University teaching hospitals
by: Valérie Labrie, et al.
Published: (2024-12-01)

Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab
by: Narek Shaverdian, et al.
Published: (2020-07-01)

Do Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment?
by: DENO Research Group, et al.
Published: (2025-01-01)

Esophagitis and Pneumonitis Related to Concurrent Chemoradiation ± Durvalumab Consolidation in Unresectable Stage III Non-Small-Cell Lung Cancer: Risk Assessment and Management Recommendations Based on a Modified Delphi Process
by: Anthony M. Brade, et al.
Published: (2024-10-01)

A pharmacovigilance analysis of post-marketing safety of durvalumab
by: An-Ju Tan, et al.
Published: (2025-05-01)

Durvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real-world data from an expanded access program in Brazil (LACOG 0120)
by: Mauro Zukin, et al.
Published: (2025-01-01)

Esophageal stenting for unresectable cancer (review of literature)
by: N. S. Popova, et al.
Published: (2021-01-01)

The use of Sirolimus for an unresectable and refractory venous malformation: A case series
by: Daniela Kristina Carolino, MD, et al.
Published: (2025-06-01)

NEW OPPORTUNITIES FOR SURGICAL TREATMENT OF PATIENTS WITH INITIALLY UNRESECTABLE UTERINE CERVIX CANCE
by: I. A. Kosenko, et al.
Published: (2016-04-01)

The role of induction chemotherapy followed by surgery in unresectable stage IVb laryngeal and hypopharyngeal cancers: a case series
by: Pichit Sittitrai, et al.
Published: (2018-10-01)

Surgical stage in sequential therapy of unresectable oral cancer T3-4bN0-3M0: evaluation of treatment results
by: Sh. I. Musin, et al.
Published: (2022-02-01)

Turtle Study: A Phase 2 Study of Durvalumab Plus Carboplatin and Etoposide in Elderly Patients With Extensive-Stage SCLC (LOGiK 2003)
by: Hidenobu Ishii, MD, PhD, et al.
Published: (2025-07-01)

Neoadjuvant chemotherapy in technically unresectable carcinoma of external auditory canal
by: Amit Joshi, et al.
Published: (2015-01-01)

Clinical outcomes of transarterial chemoembolization combined with durvalumab for advanced and metastatic biliary tract cancer
by: Yuefeng Hu, et al.
Published: (2025-12-01)

Meta-analysis of the efficacy of applying reduced surgery for the treatment of asymptomatic unresectable advanced gastric cancer
by: Xiong Li, et al.
Published: (2025-04-01)

Liver Transplantation in the Treatment of Unresectable Hepatocellular Carcinoma in the Absence of Liver Cirrhosis
by: O. D. Olisov, et al.
Published: (2018-09-01)

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
by: Emil Lou, et al.
Published: (2013-04-01)

Isolated chemohyperthermal perfusion of the liver with melphalan in the treatment of unresectable liver metastases with uveal melanoma
by: A. D. Kaprin, et al.
Published: (2021-12-01)

Disseminate Cutaneous Vasculitis Associated with Durvalumab Treatment—Case Report, Mini-Review on Cutaneous Side Effects of Immune Checkpoint Inhibitor Therapies with Machine Learning Perspectives
by: Gyula Laszlo Fekete, et al.
Published: (2024-08-01)

Tremelimumab plus durvalumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: a cost-effectiveness analysis from the US payer perspective
by: Bin Li, et al.
Published: (2025-04-01)

First-line durvalumab plus platinum–etoposide in Japanese patients with extensive-stage small-cell lung cancer
by: Eisuke Mochizuki, et al.
Published: (2025-01-01)

Differential safety profiles of durvalumab monotherapy and durvalumab in combination with tremelimumab in adult patients with advanced cancers
by: Mayur Patel, et al.
Published: (2025-05-01)

Palliative intraarterial chemoradiotherapy as a method of choice in the treatment of unresectable oropharyngeal tumors: a clinical case
by: R. V. Lutovinin, et al.
Published: (2021-01-01)

Durvalumab induced immune-related agranulocytosis after conversion surgery in a patient with intrahepatic cholangiocarcinoma: a case report
by: Yoshihito Kitamura, et al.
Published: (2025-07-01)

Successful stent removal after chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer with airway stenosis: A report of three cases
by: Yuki Takigawa, et al.
Published: (2025-01-01)

Durvalumab and pembrolizumab in advanced biliary tract cancer: a reconstructed patient-level mimic head-to-head comparative analysis
by: Bi-Cheng Wang, et al.
Published: (2024-12-01)

Stereotactic Body Radiotherapy for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Observational Study from a Regional Cancer Center in South Asia—A Case Series
by: Arunkumar M.N, et al.

Durvalumab Monotherapy in Complex Advanced Hepatocellular Carcinoma: A Real‐World Study of Patients Ineligible for Combination Immunotherapy
by: Chihiro Miwa, et al.
Published: (2025-03-01)